SAN FRANCISCO—New research has shown the alpha-emitting drug radium 233 to be a “benign” therapy with no major toxicities — while effectively targeting bone metastatic disease and increasi
SAN FRANCISCO—New research has shown the alpha-emitting drug radium 233 to be a “benign” therapy with no major toxicities — while effectively targeting bone metastatic disease and increasing overall survival in patients with castration-resistant prostate cancer whether or not they had received docetaxel therapy. At the ASCO Genitourinary Cancers Symposium Professor Sten Nilsson MD, PhD, a medical oncologist at the Karolinska Institute in Stockholm presented results from the phase III ALSYMPCA study looking at 1.5 year follow up of patients treated with radium compared to those receiving placebo. He discussed his results with AudioMedica.com and assesses the clinical role of this radiopharmaceutical.
CONTACT:
Professor Sten Nilsson MD PhD
Medical Oncologist
Karolinska Institutet
Stockholm, Sweden
SOURCE:
Abstract number: 9
LINK: http://meetinglibrary.asco.org/content/124468-142
Related Episodes
Adjuvant Chemotherapy Extends Life in Locally Advanced Bladder Cancer
ORLANDO—Adjuvant chemotherapy was found to extend life in patients with locally advanced bladder cancer in research reported to the 2015 Genitourinary Cancers Symposium. Matt Galsky MD from the Tisch
Enzalutamide in metastatic castration resistant prostate cancer: over 75s benefit too
ORLANDO, FLORIDA—Men over 75 were safely and effectively treated for their metastatic castration-resistant prostate cancer with the androgen receptor inhibitor enzalutamide in the Phase III AFFIRM stu
Low risk localized prostate cancer: no harm from waiting!
ORLANDO, FLORIDA—A decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients according to research presented to the 2013 Genitourinary Cancers Sympo